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Although evidence suggests that maternal hypothyroidism and mild hypothyroxinemia during the first half of pregnancy alters
fetal neurodevelopment among euthyroid offspring, little data are available from later in gestation. In this study, we measured free
T4 using direct equilibrium dialysis, as well as total T4 and TSH in 287 pregnant women at 27 weeks’ gestation. We also assessed
cognition, memory, language, motor functioning, and behavior in their children at 6, 12, 24, and 60 months of age. Increasing
maternal TSH was related to better performance on tests of cognition and language at 12 months but not at later ages. At 60
months, there was inconsistent evidence that higher TSH was related to improved attention. We found no convincing evidence
that maternal TH during the second half of pregnancy was related to impaired child neurodevelopment.
1. Introduction
The profound deleterious neurodevelopmental effect of
maternal and fetal hypothyroidism caused by iodine defi-
ciency has been recognized formore than a century [1].More
recent evidence from experimental and observational studies
suggests that even among euthyroid offspring, maternal
hypothyroidism and hypothyroxinemia (low thyroxine (T4)
with normal thyroid-stimulating hormone (TSH) levels)
during early pregnancy may be associated with impaired
brain development. Man and colleagues, for instance, re-
ported associations between maternal hypothyroxinemia in
early pregnancy and lower scores on neurodevelopmental
scales at 8 months, 4 years, and 7 years of age [2–4]. A more
recent study by Haddow et al. found reduced scores on tests
of intelligence, attention, and visual-motor performance at 8
years of age among children of 48 mothers with untreated
clinical hypothyroidism (defined as TSH levels >99.7th
percentile or TSH between the 98th and the 99.6th percentile
and total T4 < 7.75 μg/dL) at the 17th week of gestation
relative to 124 controls [5]. A Chinese study (n = 1, 268) also
found that children of 19 women with hypothyroxinemia
(defined as total T4 below the reference range but normal
TSH and free T4) and 18 women with subclinical hypothy-
roidism (high TSH and normal free and total T4) in the first
half of pregnancy scored 7.6–10.0 point lower than controls
on the mental (MDI) and psychomotor (PDI) development
indices of the Bayley Scales of Infant Development [6].
Studies have reported reduced scores on cognitive,
motor, and language scales even among children of moth-
ers with mild hypothyroxinemia. For instance, in a large
population-based cohort study conducted in The Nether-
lands (n = 3, 659), Henrichs et al. found 80% increased
odds of expressive language delays at 18 and 30 months of
age among children whose mother had free T4 levels <10th
percentile at 13 weeks’ gestation [7]. Pop and colleagues
also reported lower scores on the orientation cluster of the
Neonatal Behavioral Assessment Scale three weeks after birth
(n = 204) [8] and a 7.4 point decrease on the PDI at 10
months of age (n = 220) [9] in children of mothers with
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lower free T4 at 12 weeks’ gestation. They also found 8–
10 point reductions on the MDI and the PDI at 12 and
24 months of age in children of 57 mothers with low-
normal free T4 relative to 50 controls [10]. The one study to
contradict the above findings did not measure free T4 [11].
Thus, the bulk of the literature points to an association
between adverse neurodevelopmental outcomes in offspring
and maternal hypothyroidism, hypothroxinemia, and low-
normal free T4 levels during the first half of pregnancy.
Evidence suggests that TH of maternal origin may also
play a role in fetal development later in pregnancy. This
hypothesis was supported by early studies which demon-
strated that transfer of radiolabeled T4 and T3 through the
placenta continues to occur after the onset of fetal thyroid
function [12]. Maternal T4 appears to reach the fetus in
significant amounts up until birth, as evidenced by a study
conducted by Vulsma et al. [13]. In that study, T4 was
detected in the cord blood of 25 neonates with a complete
iodide organification defect, a genetic condition that pre-
vents the iodination of tyrosine and therefore inhibits T4
synthesis. T4measured in cord blood reached concentrations
equivalent to 30–60% of the mean values found in full-term
fetuses without this condition [14]. Given that a substantial
proportion of thyroid hormone reaching the fetus is of
maternal origin in the latter part of gestation, it is conceivable
that maternal thyroid hormone may continue to affect fetal
neurodevelopment during this period. To date, only the
studies by Pop and colleagues examined this question in
humans and found no relationship between low-normal
maternal free T4 (<10th percentile) measured at 24 and 32
weeks’ gestation and child neurodevelopment [8–10]. To our
knowledge, these results have not been replicated by other
groups.
Most studies investigating the association of maternal
thyroid function during pregnancy and child cognitive
development have focused on hypothyroidism/hypothy-
roxinemia, perhaps because this condition is more common
than hyperthyroidism. Maternal hyperthyroidism is nev-
ertheless a significant condition that affects 0.05–0.2% of
pregnancies in the form of Graves’ disease; an additional
2-3% of pregnant women are also believed to experience
gestational transient thyrotoxicosis [15]. In rats, fetal/neo-
natal hyperthyroidism causes decreased brain and cerebellar
weight as well as abnormal brain development, including
an acceleration of neuronal differentiation, a delay in glial
cell differentiation and early termination of cell proliferation,
resulting in a smaller number of granular and basket cells
[16]. In humans, maternal hyperthyroidism during preg-
nancy has been linked to preeclampsia, fetal loss, premature
births, growth restriction, and low birth weight [17–21].
Subclinical hyperthyroidism (defined as TSH values below
the reference range with normal free T4 levels [22]), on the
other hand, was not found to be associated with low birth
weight, major malformations, or fetal, neonatal, or perinatal
mortality in infants of 433 women with TSH levels ≤2.5th
percentile and normal free T4 (≤1.75 ng/dL) relative to
23,124 women with normal TSH levels [23]. However, we
are aware of no studies that investigated associations between
high-normal T4 or subclinical hyperthyroidism and neu-
rodevelopment.
The current study thus aims to examine whether mater-
nal TH levels in the second half of pregnancy are associated
with child neurodevelopment at 6, 12, 24, and 60 months of
age. Prior studies used immunoassays to determine free T4
levels, but these measurements are influenced by T4-bound
protein concentrations which increase during pregnancy
[24]. In the present study, we used direct equilibrium dialysis
to measure free T4 [25], a method that yields valid results
in samples with normal or elevated T4-bound protein levels
[26].
2. Methods
2.1. Participants. Pregnant women were recruited through
the Center for the Health Assessment of Mothers and
Children of Salinas (CHAMACOS), a birth cohort study
of primarily Latino children born in the Salinas Valley,
California. Women were eligible for inclusion in the study if
they were≥18 years old, had completed <20 weeks’ gestation,
spoke English or Spanish, were Medi-Cal eligible (state-
sponsored health care for low-income families), were plan-
ning to deliver at the Monterey county hospital (Natividad
Medical Center), and received prenatal care in this hospital
or at one of five clinics of Clinica de Salud del Valle de
Salinas. Screening and enrollment occurred betweenOctober
1999 and October 2000. We obtained informed consent from
the 601 women who agreed to participate. Out of the 526
singleton live births (there were 20 miscarriages, 3 stillbirths,
2 neonatal deaths, 5 twin births, and 45 women were lost
to follow-up), we excluded children with conditions that
may impact scores on neurodevelopmental tests such as
hydrocephaly (n = 1), autism (n = 1), and a history of
seizures (n = 7). Children whose neurodevelopment was
never assessed (n = 139) or whose mother’s banked serum
volume was insufficient for TH analysis (n = 91) were also
excluded, leaving a final sample of 287 mother-child pairs. A
total of 271 children were included at 6 months, 258 at 12
months, 240 at 24 months, and 207 at 60 months of age.
Women who were excluded or who dropped out at one
or more time-point were more likely to be employed, to have
been born in the US, to be depressed, and had lived longer
in the US compared to those who were included in analyses.
Excluded children were more likely to be firstborns and to
have had lower birth weights compared to those who were
included in the analyses. This study was approved by the Uni-
versity of California, Berkeley Committee for the Protection
of Human Subjects.
2.2. Interviews. Women were interviewed in English or
Spanish by bilingual, bicultural staff during pregnancy (at 13
and 27 weeks’ gestation on average), at delivery, and when
their children were 6, 12, 24, and 60 months of age. We
obtained information about sociodemographic and lifestyle
characteristics at each interview, including smoking, alcohol
consumption, drug use, and diet during pregnancy; and on
childcare, breastfeeding, number of children in the home,
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and housing density (number of people per room) after
birth. The Peabody Picture Vocabulary Test (PPVT; at the 6
month visit) [27] and the Center for Epidemiologic Studies
Depression Scale (CES-D; at the 12 month visits) [28]
were also administered to mothers. In addition, the Infant-
Toddler Home Observation for Measurement of the Envi-
ronment (HOME) [29] was completed at 6 and 12 months;
some subscales of the HOME were completed at 24 months.
We also administered the Kotelchuck Adequacy of Prenatal
Care Utilization Index [30], the Duke-UNC Functional
Social Support Questionnaire [31], and the Diet Quality
Index proposed by Bodnar and Siega-Riz [32] and modified
by Harley and Eskenazi [33]. Mothers’ (during pregnancy)
and children’s (up to age 24 months) medical records were
abstracted by a registered nurse. We obtained data on deliv-
ery complications including vacuum extraction, placental
abruption, amnionitis, and hemorrhage, or other bleeding;
and on neonatal TSH levels (see below).
2.3. Neurodevelopmental Evaluations. Children were evalu-
ated at the ages of 6, 12, 24, and 60 months. We selected
for analyses those tests that assessed the same constructs
examined in previous studies of maternal thyroid hormone
and child neurodevelopment [2–7, 9–11]. Children were
assessed at 6, 12, and 24 months of age on the Mental Devel-
opment Index (MDI) and Psychomotor Development Index
(PDI) of the Bayley Scales of Infant Development-Second
Edition [34], and at 6 and 12 months on the auditory and
expressive comprehension subscales of the Preschool Lan-
guage Scale (PLS). At 60 months of age, the Performance
Intellectual Quotient (IQ) was evaluated using the Wechsler
Preschool and Primary Scale of Intelligence 3rd edition
(WPPSI-III) [35]. We also administered the Vocabulary
subtest of the WPPSI-III. Motor and language development,
memory, attention, and school readiness were assessed using
the McCarthy Scales of Children’s Abilities (Digit Span For-
ward and Backward, Words and Sentences, Draw-a-Child,
and GrossMotor Leg and Arm) [36], theWoodcock-Johnson
Test of Cognitive Ability (Letter-Word and Applied Prob-
lems) and its Spanish-validated version (the Woodcock-
Mun˜oz Test [37, 38]), the Pegboard subtest of the Wide
Range Assessment of Visual-Motor Abilities (WRAVMA) for
both dominant and non-dominant hands [39], the Conner’s
Kiddie Continuous Performance Test (KCPT) [40], and
the PPVT [27]. The mother was queried about her child’s
behavior using the Child Behavior Checklist (CBCL). The
Bayley Scales, the WPPSI performance IQ, the WRAVMA,
the Woodcock-Johnson/Mun˜oz test, and the PPVT are age-
standardized to a mean of 100 and a standard deviation of
15. Standardized scores on the McCarthy Scales are only
available for full subscales but not for individual subtests.
Raw scores were thus used for gross motor subtests. Scores
on other McCarthy subtests were determined by subtracting
children’s chronological age from their developmental age
(in months), as determined using methods published by
Kaufman and Kaufman [41]. Positive scores show accelerated
development while negative scores represent a delay. Finally,
raw scores were used for the CBCL following recommenda-
tions from the test manual [42].
Neurodevelopmental evaluations were conducted in
Spanish and/or English by psychometricians blind to moth-
ers’ TH levels in the study office or in a recreational vehicle
(RV) modified for this purpose. Psychometricians were
trained and supervised by a child neuropsychologist (CJ) and
were videotaped and evaluated on a regular basis to ensure
consistency across psychometricians and over time. All tests
were reviewed by graduate students trained by the child
neuropsychologist to ensure accurate scoring.
2.4. Thyroid Hormone Measurements. We measured TSH,
free T4 and total T4 in serum collected by venipuncture
from pregnant women at the time of the second interview
(Mean ± SD = 26.9 ± 3.4 weeks’ gestation). Samples were
processed immediately at Natividad Medical Center and
stored at −80◦C at the UC Berkeley School of Public Health
Biorepository until shipment to Quest Diagnostic’s Nichols
Institute (San Juan Capistrano, CA) where they were ana-
lyzed on a Bayer ADVIA Centaur system (Siemens Health-
care Diagnostics, Deerfield, IL). A pilot experiment revealed
that every freeze-thaw cycle was associated with a 0.1 ng/dL
increase in free T4 levels (P < 0.001); this variable accounted
for 33% of the variance (unpublished results). Samples were
thus thawed only once for aliquoting, shipped refrigerated,
and analyzed within 48 hours. TSH was measured by
ultrasensitive third generation immunochemiluminometric
assay (ICMA; functional sensitivity (FS): 0.01mIU/L, intra-
assay coefficients of variation (CV) = 2.3–6.0%); total T4
was determined by solid-phase ICMA (FS: 0.1 μg/dL, CV:
4.5–5.7%); free T4 was analyzed by direct equilibrium
dialysis (ED) followed by radioimmunoassay (RIA; FS:
0.1 ng/dL, CV: 2.4–6.2%) [25]. Serum protein-bound T4
levels usually increase during pregnancy [15], which may
bias results obtained by immunoassays not preceded by ED
[24]. ED uses a semipermeable membrane to physically
separate the bound hormone from the free portion, which
is then measured using a highly sensitive RIA. This method
measures free T4 accurately in samples with normal or
elevated protein-bound T4 levels [26]. Previous studies used
butanol-extractable iodine [2–4], which estimates T4 levels
by measuring protein-bound iodine [43] or immunoassays
[5–10]. Trimester-specific reference ranges for TH levels were
provided by the analytical laboratory. Neonatal TSH was
also measured in dried blood spots by the Genetics Disease
Branch of the California Department of Health Services as
part of the State’s Newborn Screening Program. Hospital
staff collected blood spots by heel stick on average 24.8
hours after birth (SD = 15.5); samples were analyzed by
solid-phase, time-resolved sandwich fluoroimmunoassay
(AutoDELPHIA; PerkinElmer, Wellesley, MA).
2.5. Statistical Analyses. Multiple linear regression models
were used to evaluate associations between TH and neu-
rodevelopmental outcomes. Models were first run with TH
expressed continuously. We also ran models with TSH cate-
gorized as low (n = 43) versus normal based on trimester-
specific reference ranges provided by the analytical labo-
ratory. There were however not enough women with high
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Table 1: Demographic characteristics of study participants (n =
287).
No. (%)
Mothers
Age (years)
18–24 130 (45.3)
25–29 95 (33.1)
30–34 42 (14.6)
35–45 20 (7.0)
Race/Ethnicity
White 5 (1.7)
Latino 278 (96.9)
Other 4 (1.4)
Education
≤6th grade 121 (42.2)
7–12th grade 105 (36.6)
≥High School 61 (21.3)
Income (% poverty)
<100 171 (59.6)
100–200 105 (36.6)
>200 11 (3.8)
Country of birth
United States 32 (11.1)
Mexico 251 (87.5)
Other 4 (1.4)
Time in the USA (years)
≤5 156 (54.4)
6–10 69 (24.0)
≥11 62 (21.6)
Parity
0 91 (31.7)
≥1 196 (68.3)
Smoking during pregnancy
No 271 (94.4)
Yes 16 (5.6)
Alcohol during pregnancy (≥one serving)
No 282 (98.3)
Yes 5 (1.7)
Children
Sex
Boy 140 (48.8)
Girl 147 (51.2)
Birthweight (g)
<2500 g 10 (3.5)
2500–3500 g 149 (51.9)
>3500 g 128 (44.6)
Gestational duration (weeks)
<37 21 (7.3)
37–42 266 (92.7)
>42 0 (0.0)
TSH or with other TH measurements outside of the refer-
ence range to conduct such analyses. Therefore, to obtain
sufficient sample size and to replicate methods used in
prior studies [7–10], we dichotomized TH at the 10th and
the 90th percentile based on distributions in our sample
and at 0.8 ng/dL. Neurodevelopmental scores were expressed
continuously. We used generalized additive models with a
3-degrees-of-freedom cubic spline function to evaluate the
shape of the relationship between continuously expressed
TH and scores on neurodevelopmental assessments and to
test for linearity [44]. Since altered neurodevelopment was
hypothesized to occur at both ends of the distribution of
TH values (i.e., following an inverse U-shaped association),
scores with P values for digression from linearity <0.10 were
fit using a quadratic term while scores with a P value ≥0.10
were fit linearly in multiple regression models. Conclusions
were similar when using quadratic or linear terms. We
therefore only present results using linear terms.
We removed outliers as identified by the Generalized
Extreme Studentized Deviates Many-Outlier procedure at an
α = 0.01 [45]. Covariates considered for inclusion in models
were identified based on prior reports suggesting that they
influenced neurodevelopment (see Appendix A for a com-
plete list). They included (categorized as shown in Table 1
or as indicated below): maternal age at enrollment (con-
tinuously), race, education, income, parity (continuously),
depression (yes versus no), maternal PPVT score (continu-
ously), Diet Quality Index (continuously), Kotelchuck Ade-
quacy of Prenatal Care Utilization Index (adequate plus, ade-
quate, inadequate), Composite Social Support Index (con-
tinuously), employment status at the time of and prior to
assessments (yes versus no), smoking (yes versus no), alcohol
(yes versus no) and illegal drug (yes versus no) consumption
during pregnancy, delivery type (natural versus cesarean sec-
tion), pregnancy complications (any versus none), infant sex,
premature birth (yes versus no), months of breastfeeding
(continuously), HOME score at the time of and prior
to assessments, and psychometrician administering assess-
ments.
To ensure that neurodevelopment was not affected by
neonatal hypothyroidism, we also considered neonatal TSH
levels as a covariate. In addition, we considered the potential
confounding effect of some known neurotoxicants. Lead
was measured in maternal and cord blood samples using
graphite furnace atomic absorption spectrophotometry. As
exposure to organophosphate insecticides has been associ-
ated with altered neurodevelopment in this cohort of farm-
worker families [46, 47], this variable was also considered.
Organophosphate insecticide exposure was assessed by mea-
suring dialkyl phosphate metabolites in maternal urine col-
lected at approximately 13 and 26 weeks’ gestation by high-
resolution gas chromatography-tandem mass spectrometry
(HRGC/MS-MS) with isotope dilution quantification [48].
Measurements at the two time points were averaged and
log10-transformed. For each time point, covariates were
included in final models if they were associated with any
of the TH measurements at P < 0.10 based on analysis of
variance (ANOVA) or Pearson’s correlations.
In order to control for potential selection bias due to
exclusion from analyses and/or loss to followup, we ran all
models with and without weights determined as the inverse
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Table 2: Mean scores on neurodevelopmental scales at 6, 12, and 24 months of age.
6 Months 12 Months 24 Months
N Mean (SD) N Mean (SD) N Mean (SD)
Bayley
Mental development index 271 95.0 (7.9) 258 101.3 (9.1) 240 86.4 (11.7)
Psychomotor development index 271 96.2 (11.1) 257 107.0 (12.8) 240 98.2 (10.4)
Preschool language scale
Auditory comprehension 270 104.6 (12.9) 257 99.1 (12.9)
Expressive comprehension 270 91.1 (13.5) 257 94.5 (13.8)
Total score 270 97.7 (11.3) 257 96.6 (13.5)
Table 3: Mean scores on neurodevelopmental scales at 5 years of
age.
N Mean (SD)
Intelligence
WPPSI1
Performance IQ 207 94.7 (14.7)
Motor
WRAVMA2
Pegboard-Dominant 205 110.7 (17.4)
Pegboard-Nondominant 204 110.3 (17.2)
McCarthy
Draw-a-Child 206 3.9 (16.1)
Gross Motor-Leg 194 11.0 (2.2)
Gross Motor-Arm 202 4.1 (2.4)
Language Development
WPPSI1 Vocabulary 207 8.8 (2.6)
PPVT3 205 94.8 (17.5)
Memory
McCarthy
Words and Sentences 205 −4.5 (16.6)
Digit Span Forward 204 −15.2 (13.0)
Digit Span Backward 199 −15.3 (10.6)
School Readiness
Woodcock-Johnson/Mun˜oz
Letter-Word 199 92.4 (12.1)
Applied Problems 206 87.0 (15.8)
Attention
CBCL4
ADHD5 200 4.7 (2.8)
KCPT6
ADHD Confidence Index5 188 45.7 (17.5)
1
Weschler Preschool and Primary Scale of Intelligence.
2Wide Range Assessment of Visual Motor Ability.
3Peabody Picture Vocabulary Test.
4Child Behavior Checklist.
5Attention Deficit Hyperactivity Disorder.
6Kiddie Continuous Performance Test.
Note: We report differences between chronological and developmental ages
for the McCarthy Draw-a-Child, Words and Sentences, and Digit Span
Forward and Backward subtests (in months). Raw scores are reported for
the gross motor tasks of the McCarthy scales (no developmental ages are
available for these subtests) and for the CBCL as recommended by the test
manual [42]. Standardized scores are used for other tests.
probability of inclusion in our samples at each time-point
[49]. Probability of inclusion was determined based on
multiple logistic regression models using covariates listed in
the Statistical Analyses section as potential predictors. Model
selection was performed using a Deletion-Substitution-
Addition (DSA) algorithm, which finds the combination
of variables (including interactions and polynomials) that
minimizes cross-validated risk [50]. Results were similar with
and without this adjustment; we present results without the
adjustment. Missing covariates were imputed. In addition,
two free T4 and two TSH values below the limit of detection
(LOD) (0.1 ng/dL and 0.01mIU/L, resp.) were imputed as
half the LOD. Statistical significance was defined as P < 0.05
on two-tailed tests. TSH values were log2-transformed for
all statistical analyses. Analyses were performed using Inter-
cooled STATA, version 10.0 (StataCorp, College Station, TX)
and R, version 2.6.1 (R Foundation for Statistical Comput-
ing, Vienna, Austria).
3. Results
Mothers were mostly low-income, Mexican-born, Spanish-
speaking Latinas with a low level of education, and many
were recent immigrants to the United States (Table 1). A large
proportion of women (73.7%) lived in farmworker families.
During pregnancy, smoking was rare in this population
(5.2%), and only 2.6% of women had ≥1 serving of alcohol
per week. Mothers’ mean PPVT score was 88.0 (SD = 21.2).
Mean free and total T4 levels were 0.8 ng/dL (SD = 0.2)
and 10.5 μg/dL (SD = 1.5), respectively; the geometric mean
for TSH was 1.2mIU/L (GSD = 1.7). Nine (2.7%) women
had low free T4 (<0.5 ng/dL) and 13 (3.9%) had low total T4
(<8.0 μg/dL) levels. None of the women were hypothyroidic
based on the reference range for TSH provided by the analyti-
cal laboratory (TSH > 5.2mIU/L), but 16 were hypothyroidic
using the criteria proposed by the National Academy of Clin-
ical Biochemistry (TSH > 2.5mIU/L) [51, 52]. Five women
had high free T4 (>1.6 ng/dL), none had elevated total T4
(>17.8 and >20.1 μg/dL in the second and third trimesters,
resp.), and 43 had low TSH (<0.5 and <0.8mIU/L in the
second and third trimesters, resp.). All children had normal
TSH levels at birth (<25mIU/L).
Scores on neurodevelopmental scales when children were
aged 6, 12, 24, and 60 months are shown in Tables 2 and 3.
Except for a lowMDI score at 24 months (mean = 86.1; SD =
12.0), Bayley and PLS scores were close to the expected mean
(i.e., 100) at all time points. At 60 months of age, children
performed well on fine motor tests but scored relatively low
6 Journal of Thyroid Research
Table 4: Associations between maternal thyroid hormone levels during pregnancy (27 weeks’ gestation) and child neurodevelopment at 6,
12 and 24 months of age.
Bayley scales Preschool language scale
Mental
development
index
Psychomotor
development
index
Auditory
comprehension
Expressive
comprehension
Total score
6 Months1
Free T4
β −3.14 −3.27 −2.03 1.65 −0.10
(95% CI) (−7.65, 1.36) (−9.36, 2.82) (−9.80, 5.75) (−5.48, 8.79) (−6.45, 6.25)
Total T4
β 0.03 −0.06 −0.24 0.58 0.19
(95% CI) (−0.57, 0.62) (−0.86, 0.74) (−1.28, 0.80) (−0.37, 1.53) (−0.66, 1.05)
TSH
β 0.85 1.46 1.51 0.24 1.06
(95% CI) (−0.49, 2.18) (−0.33, 3.26) (−0.81, 3.84) (−1.91, 2.38) (−0.87, 2.98)
12 Months2
Free T4
β −0.48 −6.40 4.39 1.26 3.45
(95% CI) (−6.22, 5.26) (−13.89, 1.08) (−3.56, 12.34) (−7.20, 9.72) (−4.76, 11.67)
Total T4
β −0.12 −0.45 0.33 −0.15 0.12
(95% CI) (−0.92, 0.68) (−1.53, 0.63) (−0.79, 1.46) (−1.34, 1.04) (−1.05, 1.28)
TSH
β 1.71 0.10 2.92 0.46 1.91
(95% CI) (0.05, 3.37)∗ (−2.16, 2.35) (0.59, 5.25)∗ (−2.04, 2.95) (−0.51, 4.33)
24 Months3
Free T4
β −4.29 −2.67
(95% CI) (−11.60, 3.02) (−8.95, 3.62)
Total T4
β −0.17 0.43
(95% CI) (−1.20, 0.85) (−0.43, 1.30)
TSH
β 0.33 −1.31
(95% CI) (−1.97, 2.63) (−3.25, 0.63)
∗P < 0.05.
1Models adjusted for maternal age, employment status at enrollment and at the 6-months visit, country of birth, time lived in the US, Diet Quality Index,
blood lead levels and delivery complications; child hospitalization before 6 months, season of assessment and psychometrician.
2Models adjusted for maternal age, employment status at enrollment and at the 6 months visit, country of birth, time lived in the US, Diet Quality Index,
Kotelchuck Adequacy of Prenatal Care Utilization Index, blood lead levels, delivery complications and PPVT score; child age, preterm birth, hospitalization at
6 months and 1 year, family structure at 1 year; season, and language spoken at the time of assessment.
3Models adjusted for maternal age, income, employment status at enrollment, 6 months and 1 year, country of birth, Diet Quality Index, Kotelchuck Adequacy
of Prenatal Care Utilization Index, blood lead levels, delivery complications, PPVT score; child hospitalization at 1 year; number of children in the home at 6
months, home density at 2 years, family structure at 1 year; season, psychometrician and language of assessment.
4Since TSH was expressed on a log2 basis, β are equal to the change in neurodevelopmental outcomes for a doubling in TSH levels.
on cognitive (verbal and nonverbal), language, and memory
tests.
Table 4 shows associations between maternal thyroid
hormone levels and child scores on the Bayley and Preschool
Language scales at 6, 12, and 24 months of age. Associations
between maternal free T4 and scores on the Bayley scales
were consistently negative but none were statistically signif-
icant either in unadjusted (results not shown) or adjusted
models. Associations between Bayley scores and total T4
were also generally negative but not statistically significant.
Increasing maternal TSH was related to better performance
on the Bayley MDI and on the auditory comprehension sub-
scale of the PLS at 12 months but maternal thyroid hormone
was not related to these constructs at later points. Maternal
free and total T4 levels were not significantly associated with
scores on the PLS.
Maternal free T4, total T4, and TSH were not associated
with performance on any tests of neurodevelopment in 60-
month-old children (Table 5) with one exception: every dou-
bling in TSH levels was associated with a 0.65 point decrease
(95%CI = −1.26,−0.04) on the Attention Deficit Hyper-
activity Disorder (ADHD) subscale of the CBCL, although
there was no significant association between maternal TH
levels and CBCL Attention Problems and Pervasive Devel-
opmental Problems scales nor on child’s performance on the
KCPT (results not shown). Categorizing each measure of TH
at the 10th or 90th percentiles yielded no significant associ-
ation; subclinical hyperthyroidism was also not related with
outcomes.
4. Discussion
We found little evidence that TH levels measured around
the 27th week of gestation in mothers of euthyroid infants
living in an iodine-sufficient area [53] were associated with
child neurodevelopment. Although increasing maternal TSH
levels were associated with better performance on the Bayley
MDI at 12 months, these results did not persist at 24 months.
Similarly, a reduction in ADHD symptoms, as reported by
mothers in 60-month-old children, was not supported by
other measures of hyperactivity and/or inattention at this age
(i.e., maternal report on the Attention Problems scale of the
CBCL or child performance on the KCPT). Better Auditory
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Table 5: Associations between maternal thyroid hormone levels during pregnancy (27 weeks’ gestation) and child neurodevelopment at 5
years of age.1
Free T4 Total T4 TSH2
β (95% CI) β (95% CI) β (95% CI)
Performance IQ
WPPSI3 −4.12 (−13.73, 5.49) 0.03 (−1.35, 1.41) −2.26 (−5.27, 0.74)
Motor Development
WRAVMA4
Pegboard-Dominant −3.76 (−15.45, 7.93) −0.97 (−2.64, 0.70) 0.51 (−3.12, 4.15)
Pegboard-Nondominant −4.21 (−16.03, 7.61) −1.55 (−3.23, 0.13) 0.02 (−3.65, 3.68)
McCarthy
Draw-a-Child −5.98 (−16.74, 4.77) 0.10 (−1.44, 1.63) 0.06 (−3.27, 3.39)
Gross Motor-Leg −0.14 (−1.60, 1.32) 0.00 (−0.22, 0.22) 0.16 (−0.31, 0.63)
Gross Motor-Arm 0.08 (−1.51, 1.66) −0.04 (−0.27, 0.19) 0.04 (−0.45, 0.53)
Language Development
WPPSI3 Vocabulary −0.21 (−1.98, 1.57) −0.22 (−0.47, 0.03) −0.37 (−0.92, 0.19)
PPVT5 −2.71 (−14.18, 8.77) −0.89 (−2.54, 0.76) −1.05 (−4.66, 2.57)
Memory
McCarthy
Words and Sentences 0.10 (−11.32, 11.52) −0.55 (−2.17, 1.07) −1.44 (−4.97, 2.09)
Digit Span Forward 4.06 (−4.72, 12.83) 0.77 (−0.46, 2.00) −1.83 (−4.51, 0.86)
Digit Span Backward 4.43 (−2.55, 11.42) −0.10 (−1.13, 0.94) −0.38 (−2.63, 1.87)
School Readiness
Woodcock-Johnson/Mun˜oz
Letter-Word −1.86 (−9.33, 5.60) 0.21 (−0.88, 1.31) 1.43 (−0.94, 3.80)
Applied Problems −3.82 (−14.06, 6.42) −0.51 (−2.01, 1.00) −1.48 (−4.74, 1.78)
Attention
CBCL6
ADHD7 −0.10 (−2.03, 1.82) 0.00 (−0.28, 0.27) −0.65 (−1.26, −0.04)∗
KCPT8
ADHD7 Confidence Index 7.52 (−4.86, 19.91) 0.09 (−1.70, 1.87) −0.75 (−4.61, 3.12)
∗P < 0.05.
1Models adjusted for maternal age, income, employment status at 6 months, country of birth, Diet Quality Index, delivery complications, PPVT score; child 5-
minute APGAR, hospitalization at 1 year; number of children in home at 1 and 2 years, home density at 2 years, family structure at 1 year; season of assessment.
2Since TSH was expressed on a log2 basis, β are equal to the change in neurodevelopmental outcomes for a doubling in TSH levels.
3Weschler Preschool and Primary Scale of Intelligence.
4Wide Range Assessment of Visual Motor Ability.
5Peabody Picture Vocabulary Test.
6Child Behavior Checklist.
7Attention Deficit Hyperactivity Disorder.
8Kiddie Continuous Performance Test.
Comprehension also was noted at 12 months but not on
other tests of language (WPPSI Vocabulary and PPVT) at 60
months.
Our results are in agreement with those reported by Pop
and colleagues, the only other group that examined associa-
tions between maternal TH levels during the second half of
gestation and child neurodevelopment [8–10]. In these stud-
ies, authors reported no associations between free T4 levels
measured at 24 and 32 weeks’ gestation and infant and tod-
dler development, but did find relations with maternal thy-
roid hormone measured earlier in pregnancy. Other studies
that measured TH during the first half of pregnancy have also
reported associations with child neurodevelopment [2–10]
with a notable exception in the study by Oken et al., which
found no association between maternal TSH and total T4
at 10 weeks’ gestation and child cognition at 6 months and
3 years of age in a large study of 500 mothers and children
dyads [11]. TH of maternal origin may thus be of particular
importance to brain development before the onset of fetal
thyroid function, which occurs around midgestation [54].
Evidence for the potential role of maternal TH before the
onset of fetal thyroid function includes the detection of T4
in coelomic fluid as early as 6 weeks’ gestation [55], the fact
that nuclear T3 receptors were identified in the brain of 10
week old fetuses [56], and that T3 binding to these receptors
was detected between 9 and 13 weeks’ gestation [57].
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This study has some limitations. Women who were
excluded from analyses were more likely to be depressed and
to give birth to children of lower birth weight. This may have
introduced bias since these variables are related to both thy-
roid hormone levels and neurodevelopment. However, our
results were not substantially altered after applying inverse
probability of inclusion weights, suggesting that this poten-
tial bias may not explain our null finding. In addition, in our
study, as well as in those of Pop and colleagues [8–10], most
women were euthyroid. Hence, our findings do not preclude
the possibility that more extreme maternal thyroid hormone
levels in the latter half of pregnancy may influence fetal
neurodevelopment.
This study has a number of strengths. We examined a
wide range of domains of behavior and neurodevelopment at
multiple ages and examinedmaternal thyroid hormone using
direct equilibrium dialysis, which is currently considered
the gold standard method to measure free T4. Prior studies
exclusively used immunoassays, which, according to the
National Academy of Clinical Biochemistry, may only be
considered as free T4 “estimates” [52]. Another strength of
the present study is that we were able to consider, and control
for, a large number of potential confounders, including
exposure to neurotoxicants such as lead, cigarette smoke,
and organophosphate insecticides [58]. In addition, our pop-
ulation is demographically homogenous, further reducing
the potential for confounding. Finally, Zoeller and Rovet pro-
posed that maternal hypothyroxinemia and hypothyroidism
at the beginning of the third trimester (when we determined
thyroid function in CHAMACOS women) primarily affects
gross and fine motor skills, memory, and visuospatial skills
[59]. In this study, we evaluated these constructs using well-
validated and widely used instruments and yet found no
clear evidence of a relationship between maternal thyroid
hormone levels and child neurodevelopment.
In summary, this is the first study of maternal thyroid
hormone and child neurodevelopment to use direct equi-
librium dialysis to measure free T4. Although prior studies
did report associations between maternal clinical hypothy-
roidism and mild hypothyroxinemia during the first half of
pregnancy and cognitive impairments in children, we find no
convincing evidence that THmeasured during later gestation
is associated with neurodevelopment in euthyroid children
living in an iodine-sufficient area.
Appendices
A. Maternal Covariates
Baseline visit
Age at enrollment (years), No. (%)
18–24 130 (45.3)
25–29 95 (33.1)
30–34 42 (14.6)
34–45 20 (7.0)
Age at enrollment (years),
Mean (SD)
25.8 (5.0)
Race, No. (%)
White 5 (1.7)
Latino 278 (96.9)
Other 4 (1.4)
Education, No. (%)
≤6th grade 121 (42.2)
7–12th grade 105 (36.6)
≥High School 61 (21.3)
Income (% poverty), No. (%)
<100 171 (59.6)
100–200 105 (36.6)
>200 11 (3.8)
Average income per person per
month ($), Mean (SD)
413.8 (255.7)
Employment status, No. (%)
No 209 (72.8)
Yes 78 (27.2)
Country of birth, No. (%)
United States 32 (11.1)
Mexico 251 (87.5)
Other 4 (1.4)
Time in the USA (years), No. (%)
≤5 156 (54.4)
6 to 10 69 (24.0)
≥11 62 (21.6)
Parity, Mean (SD) 1.3 (1.2)
Smoking during pregnancy,
No. (%)
No 271 (94.4)
Yes 16 (5.6)
Smokers in household during
pregnancy, No. (%)
No 258 (89.9)
Yes 29 (10.1)
Any second-hand smoke exposure
during pregnancy, No. (%)
No 179 (62.4)
Yes 108 (37.6)
More than one alcoholic drink per
week during pregnancy, No. (%)
No 282 (98.3)
Yes 5 (1.7)
Any drug consumption during
pregnancy, No. (%)
No 282 (98.3)
Yes 5 (1.7)
Kotelchuck Adequacy of Prenatal
Care Utilization Index, No. (%)
Inadequate 62 (21.6)
Adequate 93 (32.4)
Adequate Plus 132 (46.0)
Diet Quality Index during
pregnancy, Mean (SD)
45.3 (9.7)
Composite Social Support Index,
Mean (SD)
3.7 (0.9)
Urinary DAP1metabolites during
pregnancy (nmol/L), Mean (SD)
2.1 (0.4)
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Lead levels during pregnancy
(ug/dL), Mean (SD) 1.5 (2.1)
6-Month Visit
Income (% poverty), No. (%)
<100 199 (69.3)
100–200 86 (30.0)
>200 2 (0.7)
Employment status, No. (%)
No 199 (69.3)
Yes 88 (30.7)
PPVT2 score, Mean (SD) 88.2 (21.1)
WAIS3 score, Mean (SD) 6.3 (2.6)
12-Month Visit
Income (% poverty), No. (%)
<100 179 (62.4)
100–200 99 (34.5)
>200 9 (3.1)
Employment status, No. (%)
No 198 (69.0)
Yes 89 (31.0)
Composite Social Support Index,
Mean (SD)
3.8 (1.0)
Depression, No. (%)
No 140 (48.8)
Yes 147 (51.2)
24-Month Visit
Income (% poverty), No. (%)
<100 167 (58.2)
100–200 107 (37.3)
>200 13 (4.5)
Employment status, No. (%)
No 174 (60.6)
Yes 113 (39.4)
Composite Social Support Index,
Mean (SD) 3.9 (1.0)
Three-Year Visit
Income (% poverty), No. (%)
<100 178 (62.0)
100–200 103 (35.9)
>200 6 (2.1)
Employment status, No. (%)
No 175 (61.0)
Yes 112 (39.0)
Depression, No. (%)
No 161 (56.1)
Yes 126 (43.9)
60-Month visit
Income (% poverty), No. (%)
<100 182 (63.4)
100–200 93 (32.4)
>200 12 (4.2)
Employment status, No. (%)
No 158 (55.1)
Yes 129 (44.9)
Composite Social Support Index,
Mean (SD)
3.9 (1.0)
1Dialkyl phosphates (DAPs) measured in maternal
urine (organophosphate pesticide metabolites).
2Peabody Picture Vocabulary Test (PPVT).
3Wechsler Adult Intelligence Scale (WAIS).
B. Child Covariates
Baseline visit
Sex, No. (%)
Boy 140 (48.8)
Girl 147 (51.2)
Birthweight (g), Mean (%)
<2500 10 (3.5)
2500–3500 149 (51.9)
>3500 128 (44.6)
Gestational duration (weeks),
No. (%)
≥37 266 (92.7)
<37 21 (7.3)
Cesarean section, No. (%)
No 220 (76.7)
Yes 67 (23.3)
Pregnancy complications, No. (%)
No 284 (99.0)
Yes 3 (1.0)
5-minute APGAR score, Mean
(SD)
8.9 (0.4)
Months child breastfed, Mean
(SD)
8.6 (8.2)
Neonatal TSH (mIU/L), Mean
(SD)
6.5 (3.5)
6-Month Visit
Number of children in household,
Mean (SD)
2.1 (0.4)
Housing density (people per
room), No. (%)
≤0.5 4 (1.4)
0.51–1.00 52 (18.1)
1.01–1.50 93 (32.4)
≥1.51 138 (48.1)
Lived with father, No. (%)
All the time 242 (84.3)
Most of the time 11 (3.8)
Some of the time 14 (4.9)
Not at all 20 (7.0)
HOME1 score, Mean (SD) 32.0 (4.1)
Hospitalized overnight, No. (%)
No 253 (88.2)
Yes 34 (11.8)
Age at assessment (months),
Mean (SD)
6.6 (1.1)
Medication/herbal intake within
24 hours of assessment, No. (%)
No 279 (97.2)
Yes 8 (2.8)
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Location assessment performed,
No. (%)
Office 187 (65.2)
Other 100 (34.8)
Season assessment performed,
No. (%)
January–March 68 (23.7)
April–June 71 (24.7)
July–September 77 (26.8)
October–December 71 (24.7)
Psychometrician at assessment,
No. (%)
01 117 (40.8)
07 32 (11.1)
13 42 (14.6)
16 4 (1.4)
23 92 (32.1)
12-Month Visit
Number of children in household,
Mean (SD)
2.0 (1.7)
Housing density (people per
room), No. (%)
≤0.5 1 (0.3)
0.51–1.00 55 (19.2)
1.01–1.50 105 (36.6)
≥1.51 126 (43.9)
Lived with father, No. (%)
All the time 239 (83.3)
Most of the time 11 (3.8)
Some of the time 13 (4.5)
Not at all 24 (8.4)
HOME1 score, Mean (SD) 35.9 (3.1)
Hospitalized overnight, No. (%)
No 276 (96.2)
Yes 11 (3.8)
Age at assessment (months), Mean
(SD)
12.7 (1.3)
Medication/herbal intake within
24 hours of assessment, No. (%)
No 255 (88.9)
Yes 32 (11.1)
Location assessment performed,
No. (%)
Office 190 (66.2)
Other 97 (33.8)
Season assessment performed,
No. (%)
January–March 73 (25.4)
April–June 67 (23.3)
July–September 74 (25.8)
October–December 73 (25.4)
Psychometrician at assessment,
No. (%)
01 109 (38.0)
07 83 (28.9)
23 95 (33.1)
24-Month visit
Number of children in household,
Mean (SD)
1.8 (1.5)
Housing density (people per
room), No. (%)
≤0.5 2 (0.7)
0.51–1.00 51 (17.8)
1.01–1.50 94 (32.8)
≥1.51 140 (48.8)
Lived with father, No. (%)
All the time 236 (82.2)
Most of the time 23 (8.0)
Some of the time 5 (1.7)
Not at all 23 (8.0)
HOME1 score, Mean (SD) 26.1 (2.5)
Hospitalized overnight, No. (%)
No 275 (95.8)
Yes 12 (4.2)
Age at assessment (months), Mean
(SD)
24.7 (1.2)
Medication/herbal intake within
24 hours of assessment, No. (%)
No 205 (71.4)
Yes 82 (28.6)
Location assessment performed,
No. (%)
Office 194 (67.6)
Other 93 (32.4)
Season assessment performed,
No. (%)
January–March 73 (25.4)
April–June 85 (29.6)
July–September 71 (24.7)
October–December 58 (20.2)
Psychometrician at assessment,
No. (%)
01 122 (42.5)
07 31 (10.8)
23 134 (46.7)
60-Month visit
Number of children in household,
Mean (SD)
1.9 (1.3)
Housing density (people per
room), No. (%)
≤0.5 1 (0.3)
0.51–1.00 87 (30.3)
1.01–1.50 126 (43.9)
≥1.51 73 (25.4)
Lived with father, No. (%)
All the time 221 (77.0)
Most of the time 16 (5.6)
Some of the time 11 (3.8)
Not at all 39 (13.6)
Hospitalized overnight, No. (%)
No 279 (97.2)
Yes 8 (2.8)
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Attended preschool, No. (%)
No 124 (43.2)
Yes 163 (56.8)
Attended kindergarten, No. (%)
No 68 (23.7)
Yes 219 (76.3)
Age at assessment (months), Mean
(SD)
60.7 (2.2)
Medication/herbal intake within
24 hours of assessment, No. (%)
No 240 (83.6)
Yes 47 (16.4)
Location assessment performed,
No. (%)
Office 245 (85.4)
Other 42 (14.6)
Season assessment performed,
No. (%)
January–March 76 (26.5)
April–June 72 (25.1)
July–September 86 (30.0)
October–December 53 (18.5)
Psychometrician at assessment,
No. (%)
01 117 (40.8)
21 23 (8.0)
23 32 (11.1)
43 115 (40.1)
1Home Observation for Measurement of the Environment
(H.O.M.E).
Acknowledgments
This publication was supported by grant numbers: RD
83171001 from the US Environmental Protection Agency
and P01 ES009605 from the National Institute for Environ-
mental Health Sciences. Additional funding was provided
by the University of California Institute for Mexico and the
United States (UC MEXUS), the Fonds de la Recherche en
Sante´ du Que´bec and the Canadian Institutes for Health
Research. The contents of this publication are solely the
responsibility of the authors and do not necessarily represent
funders’ official views. The authors gratefully acknowledge
study participants as well as Jon Nakamoto, MD, Ph.D.,
Michelle Vedar, MPH and Kristin M. Tyler, BA, for their
invaluable contributions. Authors declare that they have no
competing financial interests.
References
[1] J. T. Dunn, “Iodine supplementation and the prevention of
cretinism,” Annals of the New York Academy of Sciences, vol.
678, pp. 158–168, 1993.
[2] E. B. Man, R. H. Holden, and W. S. Jones, “Thyroid function
in human pregnancy. VII. Development and retardation of
4-year-old progeny of euthyroid and of hypothyroxinemic
women,” American Journal of Obstetrics and Gynecology, vol.
109, no. 1, pp. 12–19, 1971.
[3] E. B. Man and W. S. Jones, “Thyroid function in human preg-
nancy. V. Incidence ofmaternal serum low butanol-extractable
iodines and of normal gestational TBG and TBPA capaci-
ties; Retardation of 8-month-old infants,” American Journal
of Obstetrics and Gynecology, vol. 104, no. 6, pp. 898–908, 1969.
[4] E. B. Man and S. A. Serunian, “Thyroid function in human
pregnancy. IX. Development or retardation of 7 year old
progeny of hypothyroxinemic women,” American Journal of
Obstetrics and Gynecology, vol. 125, no. 7, pp. 949–957, 1976.
[5] J. E. Haddow, G. E. Palomaki,W. C. Allan et al., “Maternal thy-
roid deficiency during pregnancy and subsequent neuropsy-
chological development of the child,”TheNew England Journal
of Medicine, vol. 341, no. 8, pp. 549–555, 1999.
[6] Y. Li, Z. Shan, W. Teng et al., “Abnormalities of maternal
thyroid function during pregnancy affect neuropsychological
development of their children at 25-30 months,” Clinical
Endocrinology, vol. 72, no. 6, pp. 825–829, 2010.
[7] J. Henrichs, J. J. Bongers-Schokking, J. J. Schenk et al., “Mater-
nal thyroid function during early pregnancy and cognitive
functioning in early childhood: the generation R study,” Jour-
nal of Clinical Endocrinology and Metabolism, vol. 95, no. 9,
pp. 4227–4234, 2010.
[8] L. Kooistra, S. Crawford, A. L. Van Baar, E. P. Brouwers, and V.
J. Pop, “Neonatal effects of maternal hypothyroxinemia during
early pregnancy,” Pediatrics, vol. 117, no. 1, pp. 161–167, 2006.
[9] V. J. Pop, J. L. Kuijpens, A. L. Van Baar et al., “Low maternal
free thyroxine concentrations during early pregnancy are asso-
ciated with impaired psychomotor development in infancy,”
Clinical Endocrinology, vol. 50, no. 2, pp. 147–155, 1999.
[10] V. J. Pop, E. P. Brouwers, H. L. Vader, T. Vulsma, A. L. Van Baar,
and J. J. De Vijlder, “Maternal hypothyroxinaemia during early
pregnancy and subsequent child development: a 3-year follow-
up study,” Clinical Endocrinology, vol. 59, no. 3, pp. 282–288,
2003.
[11] E. Oken, L. E. Braverman, D. Platek, M. L. Mitchell, S. L. Lee,
and E. N. Pearce, “Neonatal thyroxine, maternal thyroid func-
tion, and child cognition,” Journal of Clinical Endocrinology
and Metabolism, vol. 94, no. 2, pp. 497–503, 2009.
[12] N. B. Myant, “Passage of thyroxine and tri-iodol-thyronine
from mother to foetus in pregnant women,” Clinical Science,
vol. 17, no. 1, pp. 75–79, 1958.
[13] T. Vulsma, M. H. Gons, and J. J. M. De Vijlder, “Maternal-
fetal transfer of thyroxine in congenital hypothyroidism due
to a total organification defect or thyroid agenesis,” The New
England Journal of Medicine, vol. 321, no. 1, pp. 13–16, 1989.
[14] J. G. Thorpe-Beeston, K. H. Nicolaides, C. V. Feelton, J. Butler,
and A. M. McGregor, “Maturation of the secretion of thyroid
hormone and thyroid-stimulating hormone in the fetus,” The
New England Journal of Medicine, vol. 324, no. 8, pp. 532–536,
1991.
[15] D. Glinoer, “The regulation of thyroid function in pregnancy:
pathways of endocrine adaptation from physiology to pathol-
ogy,” Endocrine Reviews, vol. 18, no. 3, pp. 404–433, 1997.
[16] I. M. Evans, M. R. Pickard, A. K. Sinha, A. J. Leonard, D. C.
Sampson, and R. P. Ekins, “Influence of maternal hyperthy-
roidism in the rat on the expression of neuronal and astrocytic
cytoskeletal proteins in fetal brain,” Journal of Endocrinology,
vol. 175, no. 3, pp. 597–604, 2002.
[17] J. Anselmo, D. Cao, T. Karrison, R. E. Weiss, and S. Refetoff,
“Fetal loss associated with excess thyroid hormone exposure,”
Journal of the AmericanMedical Association, vol. 292, no. 6, pp.
691–695, 2004.
12 Journal of Thyroid Research
[18] M. Phoojaroenchanachai, S. Sriussadaporn, T. Peerapatdit et
al., “Effect of maternal hyperthyroidism during late pregnancy
on the risk of neonatal low birth weight,” Clinical Endocrinol-
ogy, vol. 54, no. 3, pp. 365–370, 2001.
[19] L. K. Millar, D. A. Wing, A. S. Leung, P. P. Koonings, M.
N. Montoro, and J. H. Mestman, “Low birth weight and
preeclampsia in pregnancies complicated by hyperthyroid-
ism,” Obstetrics and Gynecology, vol. 84, no. 6, pp. 946–949,
1994.
[20] J. H. Lazarus, “Thyroid disease in pregnancy and childhood,”
Minerva Endocrinologica, vol. 30, no. 2, pp. 71–87, 2005.
[21] S. Luewan, P. Chakkabut, and T. Tongsong, “Outcomes
of pregnancy complicated with hyperthyroidism: a cohort
study.,” Archives of Gynecology and Obstetrics, vol. 283, no. 2,
pp. 243–247, 2011.
[22] M. I. Surks, E. Ortiz, G. H. Daniels et al., “Subclinical thyroid
disease: scientific review and guidelines for diagnosis and
management,” Journal of the American Medical Association,
vol. 291, no. 2, pp. 228–238, 2004.
[23] B. M. Casey, J. S. Dashe, C. E. Wells, D. D. McIntire, K. J.
Leveno, and F. G. Cunningham, “Subclinical hyperthyroidism
and pregnancy outcomes,”Obstetrics and Gynecology, vol. 107,
no. 2 I, pp. 337–341, 2006.
[24] R. Wang, J. C. Nelson, R. M. Weiss, and R. B. Wilcox, “Accu-
racy of free thyroxine measurements across natural ranges of
thyroxine binding to serum proteins,” Thyroid, vol. 10, no.
1, pp. 31–39, 2000.
[25] J. C. Nelson and R. T. Tomei, “Direct determination of
free thyroxin in undiluted serum by equilibrium dialy-
sis/radioimmunoassay,” Clinical Chemistry, vol. 34, no. 9, pp.
1737–1744, 1988.
[26] J. C. Nelson, R. M. Weiss, and R. B. Wilcox, “Underestimates
of serum free thyroxine (T4) concentrations by free T4
immunoassays,” Journal of Clinical Endocrinology and Metab-
olism, vol. 79, no. 1, pp. 76–79, 1994.
[27] L. Dunn and L. Dunn, Peabody Picture Vocabulary Test,
American Guidance Service, Circle Pines, Minn, USA, 1981.
[28] L. S. Radloff, “The CES-D scale: a self-report depression scale
for research in the general population,” Applied Psychological
Measurement, vol. 1, no. 3, pp. 385–401, 1977.
[29] B. Caldwell and R. Bradley, Home Observation for Measure-
ment of the Environment, University of Arkansas, Little Rock,
Ark, USA, 1984.
[30] M. Kotelchuck, “An evaluation of the Kessner Adequacy of
Prenatal Care Index and a proposed Adequacy of Prenatal Care
Utilization Index,” American Journal of Public Health, vol. 84,
no. 9, pp. 1414–1420, 1994.
[31] W. E. Broadhead, S. H. Gehlbach, F. V. de Gruy, and B. H.
Kaplan, “The Duke-UNC Functional Social Support Ques-
tionnaire. Measurement of social support in family medicine
patients,” Medical Care, vol. 26, no. 7, pp. 709–723, 1988.
[32] L. M. Bodnar and A. M. Siega-Riz, “A diet quality index for
pregnancy detects variation in diet and differences by sociode-
mographic factors,” Public Health Nutrition, vol. 5, no. 6, pp.
801–809, 2002.
[33] K. Harley and B. Eskenazi, “Time in the United States,
social support and health behaviors during pregnancy among
women of Mexican descent,” Social Science and Medicine, vol.
62, no. 12, pp. 3048–3061, 2006.
[34] N. Bayley, Bayley Scales of Infant Development, The Psycholog-
ical Corporation, San Antonio, Tex, USA, 2nd edition, 1993.
[35] D. Wechsler, WPPSI-III Administration and Scoring Manual,
The Psychological Corporation, San Antonio, Tex, USA, 2002.
[36] D. McCarthy, Manual for the McCarthy Scales of Children’s
Abilities, The Psychological Corporation, New York, NY, USA,
1972.
[37] R. W. Woodcock and A. F. Munoz-Sandoval, Bateria Wood-
cock-Munoz: Pruebas de Habilidad Cognitiva-Revisada, The
Riverside Publishing Company, Itasca, III, USA, 1996.
[38] R. W. Woodcock and M. B. Johnson, Woodcock-Johnson Tests
of Cognitive Ability, The Riverside Publishing Company, Itasca,
III, USA, 1990.
[39] W. Adams and D. Sheslow, WRAVMA: Wide Range Assessment
of Visual Motor Abilities, Wide Range, Wilmington, Del, USA,
1995.
[40] C. K. Conners, Conners’ K-CPT: Kiddie Continuous Perfor-
mance Test, Multi-Health Systems, North Tonawanda, NY,
USA, 2001.
[41] A. S. Kaufman andN. L. Kaufman,Clinical Evaluation of Young
Children with the McCarthy Scales, Grune & Stratton, New
York, NY, USA, 1977.
[42] T. M. Achenbach and L. A. Rescorla, Manual for the ASEBA
Preschool Forms & Profiles, University of Vermont, Research
Center for Children, Youth & Families, Burlington, Vt, USA,
2000.
[43] E. B. Man, D. M. Kudd, and J. P. Peters, “Butanol-extractable
iodine of serum,” The Journal of Clinical Investigation, vol. 30,
no. 5, pp. 531–538, 1951.
[44] T. Hastie and R. Tibshirani, “Generalized additive models for
medical research,” Statistical Methods in Medical Research, vol.
4, no. 3, pp. 187–196, 1995.
[45] B. Rosner, “Percentage points for a generalized ESD many-
outlier procedure,” Technometrics, vol. 25, no. 2, pp. 165–172,
1983.
[46] J. G. Young, B. Eskenazi, E. A. Gladstone et al., “Association
between in utero organophosphate pesticide exposure and
abnormal reflexes in neonates,” NeuroToxicology, vol. 26, no.
2, pp. 199–209, 2005.
[47] B. Eskenazi, A. R. Marks, A. Bradman et al., “Organophos-
phate pesticide exposure and neurodevelopment in young
Mexican-American children,” Environmental Health Perspec-
tives, vol. 115, no. 5, pp. 792–798, 2007.
[48] R. Bravo, L. M. Caltabiano, G. Weerasekera et al., “Mea-
surement of dialkyl phosphate metabolites of organophos-
phorus pesticides in human urine using lyophilization with
gas chromatography-tandem mass spectrometry and isotope
dilution quantification,” Journal of Exposure Analysis and
Environmental Epidemiology, vol. 14, no. 3, pp. 249–259, 2004.
[49] J. W. Hogan, J. Roy, and C. Korkontzelou, “Tutorial in bio-
statistics. Handling drop-out in longitudinal studies,” Statistics
in Medicine, vol. 23, no. 9, pp. 1455–1497, 2004.
[50] S. E. Sinisi and M. J. van der Laan, “Loss-based cross-
validated deletion/substitution/addition algorithms in estima-
tion,” UC Berkeley Division of Biostatistics Working Paper
Series, Working Paper 143, 2004, http://www.bepress.com/
ucbbiostat/paper143.
[51] S. J. Mandel, C. A. Spencer, and J. G. Hollowell, “Are detection
and treatment of thyroid insufficiency in pregnancy feasible?”
Thyroid, vol. 15, no. 1, pp. 44–53, 2005.
[52] National Academy of Clinical Biochemistry, “Laboratory
support for the diagnosis of thyroid disease,” in Laboratory
Medicine Practice Guidelines, L. M. Demers and C. A. Spencer,
Eds., NACB, Washington, DC, USA, 2002.
[53] K. L. Caldwell, G. A. Miller, R. Y. Wang, R. B. Jain, and R. L.
Jones, “Iodine status of the U.S. population, National Health
and Nutrition Examination Survey 2003-2004,” Thyroid, vol.
18, no. 11, pp. 1207–1214, 2008.
Journal of Thyroid Research 13
[54] G. Morreale De Escobar, M. J. Obregon, and F. Escobar Del
Rey, “Clinical perspective: is neuropsychological development
related to maternal hypothyroidism or to maternal hypothy-
roxinemia?” Journal of Clinical Endocrinology and Metabolism,
vol. 85, no. 11, pp. 3975–3987, 2000.
[55] B. Contempre, E. Jauniaux, R. Calvo, D. Jurkovic, S. Campbell,
and G. M. De Escobar, “Detection of thyroid hormones in
human embryonic cavities during the first trimester of preg-
nancy,” Journal of Clinical Endocrinology and Metabolism, vol.
77, no. 6, pp. 1719–1722, 1993.
[56] J. Bernal and F. Pekonen, “Ontogenesis of the nuclear
3,5,3’-triiodothyronine receptor in the human fetal brain,”
Endocrinology, vol. 114, no. 2, pp. 677–679, 1984.
[57] B. Ferreiro, J. Bernal, C. G. Goodyer, and C. L. Branchard,
“Estimation of nuclear thyroid hormone receptor saturation
in human fetal brain and lung during early gestation,” Journal
of Clinical Endocrinology and Metabolism, vol. 67, no. 4, pp.
853–856, 1988.
[58] J. Chevrier, B. Eskenazi, A. Bradman, L. Fenster, andD. B. Barr,
“Associations between prenatal exposure to polychlorinated
biphenyls and neonatal thyroid-stimulating hormone levels in
a Mexican-American population, Salinas Valley, California,”
Environmental Health Perspectives, vol. 115, no. 10, pp. 1490–
1496, 2007.
[59] R. T. Zoeller and J. Rovet, “Timing of thyroid hormone action
in the developing brain: clinical observations and experimen-
tal findings,” Journal of Neuroendocrinology, vol. 16, no. 10, pp.
809–818, 2004.
